利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性

刘佳楠 董宇

[摘要] 目的 探討利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性。 方法 选择2019年3～4月在我院诊断治疗的2型糖尿病患者100例为研究对象，BMI≥28 kg/m2。随机分为观察组与对照组各50例。对照组给予盐酸二甲双胍缓释片治疗，观察组在此基础上加用利拉鲁肽注射液治疗。比较两组治疗后血糖水平、体质量、BMI、腰围及不良反应。 结果 （1）治疗后，两组FBG、2 h PBG、HbA1c水平均较治疗前显著下降（P<0.05）;治疗后，观察组FBG、2 h PBG、HbA1c水平显著低于对照组（P<0.05）。（2）两组治疗后体质量、BMI、腰围均较治疗前显著下降（P<0.05）;治疗后观察组体质量、BMI、腰围均显著低于对照组（P<0.05）。（3）两组治疗期间不良反应比较差异无统计学意义（P>0.05）。 结论 利拉鲁肽治疗肥胖2型糖尿病具有较好的临床疗效及安全性。

[关键词] 肥胖;2型糖尿病;GLP-1受体激动剂;利拉鲁肽;盐酸二甲双胍缓释片

[中图分类号] R587.1          [文献标识码] B          [文章编号] 1673-9701（2020）15-0127-04

Clinical efficacy and safety of liraglutide in the treatment of patients with obesity and type 2 diabetes

LIU Jia'nan   DONG Yu

Department of Pharmacy，the Central Hospital of Jiamusi City in Heilongjiang Province，Jiamusi   154002，China

[Abstract] Objective To explore the clinical efficacy and safety of liraglutide in the treatment of patients with obesity and type 2 diabetes. Methods 100 patients with type 2 diabetes who were diagnosed and treated in our hospital from March to April 2019 were selected as the research subjects，with BMI≥28 kg/m2. They were randomly divided into observation group and control group， with 50 cases in each group. The control group was given metformin hydrochloride sustained-release tablets，and the observation group was given liraglutide injection on the basis of the control group. The blood glucose level，body mass，BMI，waist circumference and adverse reactions were compared between the two groups after treatment. Results （1）After treatment，the levels of FBG，2 h PBG and HbA1c in the two groups were significantly lower than those before treatment（P<0.05）; after treatment，the levels of FBG， 2 h PBG and HbA1c in the observation group were significantly lower than those in the control group（P<0.05）. （2） The body weight， BMI and waist circumference in both groups after treatment were significantly decreased compared with those before treatment（P<0.05）; the body mass， BMI and waist circumference in the observation group were significantly lower than those in the control group after treatment（P<0.05）. （3）There was no statistically significant difference in adverse reactions between the two groups during treatment（P>0.05）. Conclusion Liraglutide has a good clinical efficacy and safety in the treatment of obesity complicated with type 2 diabetes.

[Key words] Obesity; Type 2 diabetes; GLP-1 receptor agonist; Liraglutide; Metformin hydrochloride sustained-release tablets

我国是糖尿病患者最多的国家，在过去的30年来，我国糖尿病发病率急剧上升，在2013年的调查中，发病率为10.9%，在此调查中，估计中国糖尿病前期的患病率为35.7%。老年人、男性、城市居民、经济发达地区、超重、肥胖者患病率更高;同样，老年人、男性、超重和肥胖者糖尿病前期的患病率更高[1]。可见肥胖与糖尿病的发病具有一定的相关性，肥胖可能增加胰岛素抵抗，导致血糖水平升高。胰高血糖素样肽-1（Glucagon like peptide-1，GLP-1）受体激动剂是一种新型的治疗2型糖尿病的药物[2，3]。GLP-1主要由回肠和结肠L细胞分泌，与受体结合后，发挥血糖依赖性的肠促胰岛素分泌[4]。GLP-1受体激动剂通过促进胰岛素分泌，控制血糖，使患者获益。本文分析肥胖2型糖尿病患者GLP-1受体激动剂治疗的临床疗效及安全性，以期为临床治疗提供参考，现报道如下。

1 资料与方法

1.1 一般资料

选择2019年3～4月在我院诊断治疗的2型糖尿病患者100例为研究对象。……